Ipertrofan

Mepartricin, the active ingredient in Ipertrofan, is a macrolide antibiotic presented as an oral tablet for oral use. It exhibits antibacterial and anti‑inflammatory properties and is used primarily in the treatment of chronic prostatitis, chronic pelvic pain syndrome, and other urogenital inflammatory disorders.

GNH USA supplies Ipertrofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Ipertrofan (Mepartricin) is used in the management of urogenital inflammatory conditions, particularly chronic prostatitis.

- Chronic prostatitis: reduces bacterial load and inflammation in the prostate gland - Chronic pelvic pain syndrome: alleviates pain and improves urinary symptoms - Benign prostatic hyperplasia‑related inflammation: helps control the inflammatory component

Common side effects are generally mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset - Diarrhea: loose stools occurring during therapy - Abdominal pain: cramping or discomfort in the abdomen - Headache: transient head pain - Dizziness: light‑headed sensation - Taste alteration: metallic or unusual taste perception

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling - Stevens‑Johnson syndrome: severe skin blistering - Hepatic dysfunction: elevated liver enzymes - Severe neutropenia: markedly reduced white blood cells - Anaphylaxis: rapid onset of life‑threatening symptoms

Before initiating therapy, consider the following precautions.

- Liver function assessment: evaluate hepatic enzymes prior to use - Renal impairment: adjust therapy in patients with severe kidney disease - Hypersensitivity: avoid if known allergy to macrolides - Concomitant macrolides: do not combine with other macrolide antibiotics - Pregnancy and lactation: use only if benefits outweigh potential risks - Store below 25°C: keep in the original pack, protect from moisture

Mepartricin may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - QT‑prolonging agents: increased risk of cardiac arrhythmia - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Mepartricin levels - Other macrolide antibiotics: additive toxicity risk

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation - Statins (e.g., simvastatin): heightened risk of myopathy - Antacids containing aluminum or magnesium: may reduce absorption - Oral contraceptives: potential reduction in efficacy, advise additional contraception